相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice
Sonia Burgaz et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2021)
Monocyclic Quinone Structure-Activity Patterns: Synthesis of Catalytic Inhibitors of Topoisomerase II with Potent Antiproliferative Activity
Thomas M. Waugh et al.
CHEMMEDCHEM (2020)
The Oxidation of Phytocannabinoids to Cannabinoquinoids
Diego Caprioglio et al.
JOURNAL OF NATURAL PRODUCTS (2020)
Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis
Carmen Navarrete et al.
NEUROBIOLOGY OF DISEASE (2020)
Isomeric O-methyl cannabidiolquinones with dual BACH1/NRF2 activity
Laura Casares et al.
REDOX BIOLOGY (2020)
Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors
Anna Macieja et al.
MOLECULAR BIOLOGY REPORTS (2019)
Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease
Sonia Burgaz et al.
MOLECULES (2019)
Bioactive products from singlet oxygen photooxygenation of cannabinoids
Ahmed Galal Osman et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor
Concepcion Garcia et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy
Carmen Navarrete et al.
JOURNAL OF NEUROINFLAMMATION (2018)
EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis
Adela Garcia-Martin et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis
Carmen Rodriguez-Cueto et al.
BIOCHEMICAL PHARMACOLOGY (2018)
VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways
Carmen del Rio et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity
Belen Palomares et al.
SCIENTIFIC REPORTS (2018)
Update on cardiotoxicity of anti-cancer treatments
Gian Marco Rosa et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2016)
VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease
Javier Diaz-Alonso et al.
SCIENTIFIC REPORTS (2016)
The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways
Carmen del Rio et al.
SCIENTIFIC REPORTS (2016)
Selective, Nontoxic CB2 Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer
Paula Morales et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
HU-331 Is a Catalytic Inhibitor of Topoisomerase Ilα
Kellie M. Regal et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2014)
A Cannabigerol Derivative Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis
Francisco J. Carrillo-Salinas et al.
PLOS ONE (2014)
Synthetic cannabinoid quinones: Preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity
Paula Morales et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Cyclohexa-2,5-diene-1,4-dione-based antiproliferative agents: design, synthesis, and cytotoxic evaluation
Carmen Petronzi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis
Aitor G. Granja et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2012)
Cannabidiol hydroxyquinone-induced apoptosis of splenocytes is mediated predominantly by thiol depletion
Hsin-Ying Wu et al.
TOXICOLOGY LETTERS (2010)
Generation of reactive oxygen species during mouse hepatic microsomal metabolism of cannabidiol and cannabidiol hydroxy-quinone
Noriyuki Usami et al.
LIFE SCIENCES (2008)
A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: A comparative in vivo study
Natalya M. Kogan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor
Natalya M. Kogan et al.
MOLECULAR CANCER THERAPEUTICS (2007)
HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity
Maximilian Peters et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells
Natalya M. Kogan et al.
MOLECULAR PHARMACOLOGY (2006)
Synthesis and antitumor activity of quinonoid derivatives of cannabinoids
NM Kogan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia
X Thomas et al.
ANNALS OF HEMATOLOGY (2002)
Medical efficacy of cannabinoids and marijuana: A comprehensive review of the literature
SM Bagshaw et al.
JOURNAL OF PALLIATIVE CARE (2002)
Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding
MM Aung et al.
DRUG AND ALCOHOL DEPENDENCE (2000)
分享论文
